|
Protocol 109
Protocol 109 is not a drug trial. To quote from the literature it is "A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/neu Intracellular Domain in Subjects with HER-2neu (HER2) Overexpressing tumors."
Study Population: Breast cancer: Stage III or Stage IV breast cancer in remission and defined as NED (no evidence of disease).
You can contact Patricia Fintak at University of Washington for more information.
Mary
|